UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Korean kimchi may boost immune function, according to a new study. Researchers found measurable changes in immune cell ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...

Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...

Company to Initiate First-in-Human Phase 1 Clinical Trial in Q2 2026ROCKVILLE, Md.--(BUSINESS WIRE)--#Clinicaltrials--Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...